Stay updated on Extension Study for KarXT Safety in Schizophrenia Clinical Trial
Sign up to get notified when there's something new on the Extension Study for KarXT Safety in Schizophrenia Clinical Trial page.

Latest updates to the Extension Study for KarXT Safety in Schizophrenia Clinical Trial page
- Check2 days agoChange DetectedThe page's revision tag was updated from v3.5.2 to v3.5.3, indicating a new release/version of the page. This change reflects a minor update to the page's release notes/history without altering the study details visible to users.SummaryDifference0.0%

- Check9 days agoChange DetectedAdded a link section for **Schizophrenia** related topics, including **MedlinePlus Genetics**.SummaryDifference0.0%

- Check17 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2. No other content appears to be affected.SummaryDifference0.0%

- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedSponsor attribution updated to Karuna Therapeutics, Inc., a Bristol Myers Squibb company, replacing Karuna Therapeutics.SummaryDifference0.1%

- Check38 days agoChange DetectedFooter revision badge updated from Revision: v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check45 days agoChange DetectedAdded Local Institution - 315 and related topics (Schizophrenia; MedlinePlus Genetics). Removed contact details for UMHAT 'Dr Georgi Stranski' and Maya Stoimenova-Popova at Site 315.SummaryDifference0.3%

Stay in the know with updates to Extension Study for KarXT Safety in Schizophrenia Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Extension Study for KarXT Safety in Schizophrenia Clinical Trial page.